Dornase Alpha
- Atc Codes:R05CB13
- CAS Codes:143831-71-4
- PHARMGKB ID:143831-71-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
Brand Names
Europe
Austria: Pulmozyme; Belgium: Pulmozyme; Bulgaria: Pulmozyme; Cyprus: Pulmozyme; Czech Republic: Pulmozyme; Denmark: Pulmozyme; Estonia: Pulmozyme; Finland: Pulmozyme; France: Pulmozyme; Germany: Pulmozyme; Greece: Pulmozyme; Hungary: Pulmozyme; Ireland: Pulmozyme; Italy: Pulmozyme; Latvia: Pulmozyme; Lithuania: Pulmozyme; Luxembourg: Pulmozyme; Malta: Pulmozyme; Netherlands: Pulmozyme; Poland: Pulmozyme; Portugal: Pulmozyme; Romania: Pulmozyme; Slovakia: Pulmozyme; Slovenia: Pulmozyme; Spain: Pulmozyme; Sweden: Pulmozyme; UK: Pulmozyme.
North America
Canada: Pulmozyme; USA: Pulmozyme.
Latin America
Brazil: Pulmozyme.
Drug combinations
Chemistry
Dornase Alpha: C~1321~H~1995~N~339~O~396~S~9~ (protein moiety). Mw: 29,249.62. Deoxyribonuclease (human clone 18-1 protein moiety). CAS-143831-71-4 (1997).
Pharmacologic Category
Enzymes. Mucolytic Agents. (ATC-Code: R05CB13).
Mechanism of action
Dornase alpha is a biosynthetic (recombinant DNA origin) form of human deoxyribonuclease I (DNase I), an enzyme that selectively cleaves extracellular DNA (e.g. in purulent pulmonary secretions), thus reducing mucous viscosity and as a result, airflow in the lung is improved and the risk of bacterial infection may be decreased.
Therapeutic use
Management of cystic fibrosis patients to reduce the frequency of respiratory infections which require parenteral antibiotics in FVC≥40%. In conjunction with standard therapies, to improve pulmonary function in cystic fibrosis.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. There are no adequate, well-controlled studies in pregnant women. Use with caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to dornase alpha, Chinese hamster ovary cell products, or any component of the formulation.
Warnings and precautions
In decreased pulmonary function, dornase alpha does not significantly reduce the risk of respiratory infections which require parenteral antibiotics. Increased incidence of cough, rhinitis, and rash in children <5 years of age compared with children ≥5 years of age.